2cureX launches world’s first CE-marked microtumor test service
September 14, 2020
2cureX, pioneers in the use of 3D microtumors in cancer therapy, announces today that IndiTreat® is now available for clinics throughout the EU. Through the fulfillment of CE marking, EU registered clinics can use the IndiTreat Test to match an individual cancer patient to the most effective cancer treatment.
Important milestone: “This is an important moment for our company,” says CEO Professor Ole Thastrup. “Our clinical partners, investors and collaborators have helped us reach this important milestone. Close interaction with oncologists will be instrumental to our commercial success. That is why we are choosing to launch IndiTreat® at ESMO, the largest oncology conference in Europe with more than 25.000 participating healthcare professionals within Oncology”
Landmark technology: “IndiTreat® provides oncologists a new tool that can reveal efficacy and resistance to guideline- and off-label based cancer treatments,” says CMO Dr. Henrik Harling. “In combination with ongoing genomic studies, IndiTreat® gets us one step closer to predict efficacy and resistance. We can now routinely make treatment decisions based on a functional test.”
Ready to roll-out: “2cureX is the first company in the world to offer a CE IVD validated functional cancer drug sensitivity test based on patient-derived microtumors,” says CBO Maarten van den Linden. “We have distributors and logistics in place to ensure that patient tumor biopsy samples are delivered securely to our laboratories. In-clinic testing has been established at our test facilities in Copenhagen and in Hamburg”.
For more information about our launch activities at ESMO, please visit us at:
the 2cureX virtual ESMO booth at https://ESMO.2cureX.com
For more information about 2cureX, please contact:
Telefon: +46 8 121 576 90
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.
IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom.
IndiTreat® is presently being marketed into the European market.
The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”).